Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
Rebiotix Inc., a Ferring Company
About
  2. Companies
  3. Rebiotix Inc., a Ferring Company
  4. News
8 News & Press Releases found

Rebiotix Inc., a Ferring Company news

Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties

  • Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as a whole, comprising the largest, most robust program ever conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection (rCDI)
  • Only gut microbiome research program with five clinical studies demonstrating consistent safety, efficacy and durability
Sep. 29, 2021

Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021

  • Analysis of data from five RBX2660 prospective studies is one of only four abstracts to receive the coveted IDWeek 2021 Program Committee Choice award for outstanding scientific research.
  • Ferring and Rebiotix will present new data showing an association between clinical outcomes and restoration of the microbiome
  • Research from the Phase 3 PUNCH CD3 trial on the effects of RBX2660 on deadly antimicrobial resistance genes and the restoration of bile acid composition, a
Sep. 22, 2021

Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

  • RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW)
  • RBX2660 is the first microbiota-based live biotherapeutic to demonstrate efficacy as early as first recurrence of Clostridioides difficile (C. difficile) infection
  • RBX2660 Phase 3 data add to the world’s largest and most robust clinical program ever conducted in the field of microbiome-based the
May. 21, 2021

Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health

  • The collaboration aims to create standardised, stabilised live microbiota-based formulations addressing bacterial vaginosis (BV), a common vaginal infection among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues1,2,3
  • The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this patient community and help more people build families
  • The agreement
Feb. 17, 2021

Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020

  • Ferring and Rebiotix, a Ferring Company, will present two oral abstracts describing translational studies of investigational microbiome-based therapeutics RBX2660 and RBX7455 for the treatment of recurrent Clostridioides difficile (C. diff) infection
  • These data presentations strengthen the company’s leadership and scientific and clinical understanding of the two investigational therapeutics
  • CDC defines C.&nbs
Oct. 21, 2020